Clinical trials: Time Management
Relapsing Forms of Multiple Sclerosis
Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis
This is an observational cross-sectional study of Ocrelizumab or Ofatumumab administrations for Relapsing forms of Multiple Sclerosis (RMS) in selected sites in the US, the UK and Australia.
- Trial name
- TIMIOS (NCT04676555)
- Testing
- Ocrelizumab, Ofatumumab
- Where
- 2 sites in United States, Australia
- Volunteers
- 2 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia
A Study Of The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-05180999 In Healthy Adults
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of 14 days of treatment with PF-05180999 in healthy subjects.
- Trial name
- NCT01429740
- Testing
- PF-05180999
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hepatitis C
A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects
GSK2485852 is a Hepatitis C NS5B site IV non-nucleoside polymerase inhibitor being developed for the treatment of chronic HCV infection.
- Trial name
- NCT01332552
- Testing
- GSK2485852 70 mg, GSK2485852 420 mg, GSK2485852 630 mg
- Where
- 5 sites in United States
- Volunteers
- 27 people
- Sponsor
- GlaxoSmithKline
Limb Lymphoedema
Clinical Study to Assess the Efficacy and Pressure Maintenance of MOBIDERM Autofit Versus Bandages in the Management of Breast Cancer Related Lymphedema (BCRL) in Night-time Maintenance Phase.
The aim of this cross-over, randomized study is to assess the efficacy and pressure maintenance of MOBIDERM Autofit versus bandages in the management of Breast Cancer Related Lymphedema (BCRL) in night-time maintenance phase.
- Trial name
- MOBISCAN (NCT07355959)
- Testing
- MOBIDERM Autofit Armsleeve, Self-bandages
- Where
- Germany
- Volunteers
- 16 people
- Sponsor
- Thuasne